EndoPAT Device for Endothelial Dysfunction in ED
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Dec 2, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a condition called endothelial dysfunction in young men aged 30-50 who experience erectile dysfunction (ED) linked to blood vessel issues. The researchers will use a device called EndoPAT to measure how well the blood vessels are functioning before and 3 to 6 months after starting treatment with a low-dose medication known as a PDE5 inhibitor, which is commonly used for ED. Additionally, they will look at how testosterone therapy affects blood vessel function in men who have low testosterone levels.
To participate in the trial, men must be 18 years or older and have been diagnosed with either erectile dysfunction or low testosterone (hypogonadism). Unfortunately, men who do not have these conditions will not be eligible. Those who join the study can expect to undergo tests to check their blood vessel health at the beginning and again after several months of treatment. This trial is not yet recruiting participants, but it aims to gather important information about how these therapies might improve blood flow and overall sexual health in men.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Males 18 years old and above
- • Diagnosed with erectile dysfunction or hypogonadism
- Exclusion Criteria:
- • Patients without the above criteria
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newport Beach, California, United States
Patients applied
Trial Officials
Faysal A Yafi, MD
Principal Investigator
University of California, Irvine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported